Trial Profile
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 11 Feb 2018 Status changed from recruiting to discontinued.
- 08 Mar 2011 New trial record